Black Rock Inc. Precision Biosciences Inc Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.34 - $0.69 $32,558 - $66,074	-95,760 Reduced 7.88%	1,118,967 $380,000
Q2 2023 Aug 11, 2023	SELL	$0.52 - $0.91 $140,505 - $245,883	-270,202 Reduced 18.2%	1,214,727 $643,000
Q1 2023 May 12, 2023	SELL	$0.7 - $1.41 $117,672 - $237,026	-168,104 Reduced 10.17%	1,484,929 $1.11 Million
Q4 2022 Feb 13, 2023	SELL	$0.97 - $45.0 $643,301 - $29.8 Million	-663,197 Reduced 28.63%	1,653,033 $1.97 Million
Q3 2022 Nov 14, 2022	SELL	$1.22 - $40.8 $80,933 - $2.71 Million	-66,339 Reduced 2.78%	2,316,230 $3.01 Million
Q2 2022 Aug 12, 2022	SELL	$1.15 - $3.34 $2.51 Million - $7.29 Million	-2,184,121 Reduced 47.83%	2,382,569 $3.81 Million
Q1 2022 May 12, 2022	BUY	$2.96 - $7.76 $518,520 - $1.36 Million	175,176 Added 3.99%	4,566,690 $14.1 Million
Q4 2021 Feb 10, 2022	BUY	$7.4 - $11.66 $1.54 Million - $2.42 Million	207,875 Added 4.97%	4,391,514 $32.5 Million
Q3 2021 Nov 09, 2021	BUY	$9.18 - $14.15 $2.52 Million - $3.88 Million	274,066 Added 7.01%	4,183,639 $48.3 Million
Q2 2021 Aug 11, 2021	BUY	$8.07 - $12.52 $31.6 Million - $48.9 Million	3,909,573 New	3,909,573 $48.9 Million

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $657M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.